NCT00992537View on ClinicalTrials.gov

Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Type 1 Diabetics

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

insulin degludec

Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).

DRUG

insulin degludec/insulin aspart

Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).

DRUG

insulin aspart

Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).

Trial Locations (1)

41460

Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY